Please ensure Javascript is enabled for purposes of website accessibility

AstraZeneca Signs Deal With Canada to Provide 20 Million Coronavirus Vaccine Doses

By Cory Renauer – Sep 25, 2020 at 4:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Canada is the latest country to enter a big vaccine-delivery commitment with AstraZeneca.

AstraZeneca (AZN -0.33%) signed a large coronavirus vaccine-delivery deal with Canada on Friday. The big pharmaceutical company will deliver up to 20 million doses of its coronavirus vaccine candidate, AZD1222.

This isn't the first time AstraZeneca has signed a commitment to deliver enormous quantities of its coronavirus vaccine candidate before it's had a chance to prove itself safe and effective in a phase 3 clinical trial. In June, the company agreed to supply Europe with up to 400 million doses of AZD1222 with deliveries beginning by the end of the year. The company also has a deal with Brazil to provide around 30 million finished doses of the vaccine by December.

Masks and a COVID-19 vaccine.

Image source: Getty Images.

Recently, clinical trials with AZD1222 were paused around the globe after a clinical trial participant in the U.K. experienced an adverse event serious enough to require hospitalization. Following inspections from independent data monitors, phase 3 studies around the globe have been allowed to continue, with the exception of one key location. To date, clinical trials with AZD1222 in the U.S. are still paused.

AZD1222 employs the hollowed-out husk of a different virus to deliver blueprints for portions of SARS-CoV-2, the virus responsible for COVID-19. The viral vector AZD1222 uses can't replicate itself, but there's always a slight chance a significant percentage of the population will have immune systems that overreact to a delivery vehicle that never elicits reactions otherwise

At the moment, there are nine SARS-CoV-2 vaccine candidates in clinical trials, but AZD1222 is arguably in the lead despite its recent hold-up. In late June, AZD1222 became the first experimental vaccine program to begin a phase 3 trial, sponsored by concerned entrepreneurs in Brazil. 

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$65.99 (-0.33%) $0.22

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
351%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.